ELF key visual

The ELF Test

Assess the risk of disease progression in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) with a simple blood test 

The Enhanced Liver Fibrosis (ELF™) Test is a simple solution to this complex problem with the power to improve outcomes for millions of advanced NASH patients.

Easy to obtain, administer, and interpret, the ELF Test is a routine blood test proven to predict progression to cirrhosis and liver related events in patients with NASH with advanced fibrosis (F3 or F4).3 Enabling accessible, effortless testing, the ELF Test simplifies and accelerates the identification of NASH patients with advanced fibrosis who may benefit most from potentially life-saving preemptive care; an important first-step in turning the tide against the liver’s silent killer.

ELF test test tube
  • Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.1,2
  • Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and LREs.3
  • Enhance patient management with a blood test that facilitates more frequent prognostic assessments.

Learn more about the Enhanced Liver Fibrosis (ELFTM) Test, the first blood test to be granted De Novo Marketing Authorization by the FDA for prognosis in advanced fibrosis due to NASH. Speaker H. Roma Levy, MS., discusses how the ELF Test can address the unmet needs in prognostic evaluation of NASH.

This Webinar was recorded live on Wednesday, October 27th but is available to watch on demand here.


The Enhanced Liver Fibrosis (ELF™) Test is a noninvasive blood test that quantifies three analytes which directly contribute to liver fibrosis. ELF measurements have proven valuable for identifying patients with NASH with advanced fibrosis (F3 or F4) at risk of progressing to cirrhosis and/or LREs.

The widely studied ELF Test can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.


Interpret the ELF score using the following guidelines:

ELF Score

Risk of Disease Progression (Development of Cirrhosis or Liver-Related Events)

< 9.80

Lower

≥ 9.80 - < 11.30

Mid

≥ 11.30

Higher


Assay


By clicking Submit you consent to the processing of your above given personal data by the Siemens Healthineers company referred to under Corporate Information and for the purpose described above. Further information concerning the processing of your data can be found in the Data Privacy Policy. You are aware that you can partially or completely revoke this consent at any time for the future. Please declare your revocation to the contact address given in the Corporate Information and sent it to us via the following e-mail address: dataprivacy.func@siemens-healthineers.com.

1

2

3